Robert Winkler, MD

Robert Winkler, MD joined a stealth Biotech as Chief Medical Officer in late 2018 bringing extensive experience in Global Clinical Development with multiple regulatory approvals as well as Medical Affairs and life cycle including product launches .
Most recently, Dr. Winkler served as Senior Vice President, Head of Clinical Development Taiho Oncology. In this role, Dr. Winkler was responsible for the portfolio design and execution of all clinical oncology programs from pre- IND through Phase I – IV, including leading Taiho’s first several global approvals for a Taiho oncology product . Over the 18 years of Dr. Winkler’s biopharmaceutical industry experience he held international roles of increasing responsibilities at Schering-Plough Corporation, Novartis Oncology, Amicus Therapeutics, Aptalis (Acquired by Forest Labs) and previous to Taiho at Array BioPharma.
Dr. Winkler is hematology trained and board-certified in internal medicine, receiving his M.D. cum laude from The Hebrew University & Hadassah Medical School in Jerusalem, Israel. Dr. Winkler is an author of more than 50 publications and invited speaker of numerous presentations and educational programs.